Episurf Medical in the final stages of development of an ankle implant
With three Episealer® knee implant products currently approved and on the market in Europe, Episurf Medical (NASDAQ: EPIS B) has initiated the development of a new line of personalised Episealer® implant products intended for osteochondral lesions of the talus bone in the ankle joint. Such lesions are a common and growing problem, along with few alternative treatment methods. Episurf Medical is now responding to a significant demand voiced by its network of surgeon partners. The ambition is to perform the first surgeries during Q2 2018. The new ankle implant and associated surgical